
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 1-U

CURRENT REPORT PURSUANT TO REGULATION A

Date of Report: November 17, 2020
(Date of earliest event reported)

Alzamend Neuro, Inc.

(Exact name of issuer as specified in its charter)

Delaware
(State or other jurisdiction of
Incorporation or Organization)

**3802 Spectrum Boulevard, Suite 112C
Tampa, Florida 33612**
(Full mailing address of principal executive offices)

(844) 722-6333
(Issuer's telephone number, including area code)

Title of each class of securities issued pursuant to Regulation A:
Common Stock, par value 0.0001 per share

Item 9. Other Events.

On November 16, 2020, Alzamend Neuro, Inc., a Delaware corporation (the “**Company**”), issued a press release announcing that mandatory registration is closing on the morning of its Shareholder and Investor Conference Call and Webcast to be held at 2:00 p.m. PT on November 17, 2020. The conference will be led by Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, the Company’s CEO and Director, to discuss the contents of a presentation prepared by the Company (the “**Presentation**”).

Copies of the press release and the Presentation are furnished herewith as **Exhibits 15.1** and **15.2**, respectively, and are incorporated by reference herein.

The information contained herein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall the information be deemed incorporated by reference into any of our Securities and Exchange Commission filings, except as shall be expressly set forth by specific reference in such a filing. The furnishing of the information in this Current Report on Form 1-U constitutes material investor information that is not otherwise publicly available.

This Current Report on Form 1-U and exhibits may contain these types of statements, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and reflect the Registrant’s judgment as of the date of this Current Report on Form 1-U. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as “expects,” “should,” “will,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report on Form 1-U. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented within.

EXHIBIT INDEX

Exhibit No.	Exhibit Title
15.1	Press Release issued by Alzamend Neuro, Inc., on November 16, 2020
15.2	Shareholder and Investor Conference Call and Webcast Presentation

SIGNATURES

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ALZAMEND NEURO, INC.

By: /s/ Stephan Jackman
Stephan Jackman
Chief Executive Officer

Date: November 17, 2020



Alzamend Neuro[®], Inc. Registration is Closing to Join the Shareholder and Investor Conference Call and Webcast set for Tomorrow, November 17, 2020 to Provide Update and Plans for 2021

Tampa, FL – (Business Newswire – November 16, 2020) – Alzamend Neuro[®], Inc. (“Alzamend[®]” or the “Company”) reminds shareholders, investors and all interested parties that mandatory registration is closing Tuesday morning for the conference call and webcast to be held that day November 17th at 5:00pm ET (2:00pm PT) led by Alzamend’s Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Alzamend’s CEO and Director. The conference call and webcast will provide an update on the Company’s activities and accomplishments and present the Company’s plans for 2021.

This conference call and webcast virtual meeting will be available via Zoom as well as a conference call dial-in to update current shareholders and employees of the Company, prospective investors and anyone else interested in learning more about Alzamend Neuro and the latest in research on how to develop means to combat Alzheimer’s disease, with pre-registration mandatory by all attendees. To start the pre-registration process, please use this link, <http://webinar.alzamend.com>

Mr. Ault, said, “We are looking forward to hosting this Shareholder and Investor Conference Call and Webcast and are very pleased to present the progress the Company has made with its two therapeutic treatments and the plans that will be presented for 2021 and beyond.”

For more information, Alzamend recommends that stockholders, investors and any other interested parties read the Company’s public filings and press releases available on the Company’s website, www.Alzamend.com or available at www.sec.gov.

About Alzamend Neuro

Alzamend Neuro[®], Inc., (“Alzamend[®]”) is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend[®] is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. Alzamend[®] is currently working to transition two therapeutics targeting Alzheimer’s disease (“AD”) from the preclinical stage at the University of South Florida into the clinical stage and towards full commercialization. Alzamend[®] has licensed both a patented mutant-peptide immunotherapeutic (AL002 or E22W42) for use as a treatment or vaccine and a lithium based ionic cocrystal therapy (AL001) that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with AD. There are no profound treatments today for Alzheimer’s disease. With AL001 and AL002, the Company believes that we can change that.

Forward-looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and those statements are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company cautions that these forward-looking statements are further qualified by other factors. The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

Contacts:

Email: Info@Alzamend.com or call: 1-844-722-6333

Company Website: www.Alzamend.com

Facebook: <https://www.facebook.com/AlzamendNeuro/>


Twitter: <https://twitter.com/AlzamendNeuro>

Instagram: <https://www.instagram.com/alzamendneuro/>

November 17, 2020

**Shareholder & Investor
Conference Call & Webcast**

Alzamend 





SAFE HARBOR STATEMENT

This presentation contains forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Such forward-looking statements include statements regarding, among others, (a) our expectations about possible business combinations, (b) our growth strategies, (c) our future financing plans, and (d) our anticipated needs for working capital. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "approximate," "estimate," "believe," "intend," "plan," "budget," "could," "forecast," "might," "predict," "shall" or "project," or the negative of these words or other variations on these words or comparable terminology. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found in the Annual Report and in the Semiannual Report referred to immediately below.

This presentation should be read in conjunction with the audited financial statements and related notes for the fiscal year ended April 30, 2019, contained in the Company's Annual Report on Form 1-K, as filed with the Securities and Exchange Commission on August 28, 2019.

Forward-looking statements are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements as a result of various factors, including, without limitation, changes in local, regional, national or global political, economic, business, competitive, market (supply and demand) and regulatory conditions and the following:

- Our ability to effectively execute our business plan;
- Our ability to manage our expansion, growth and operating expenses;
- Our ability to evaluate and measure our business, prospects and performance metrics;
- Our ability to compete and succeed in a highly competitive and evolving industry;
- Our ability to respond and adapt to changes in technology and customer behavior; and
- Our ability to protect our intellectual property and to develop, maintain and enhance a strong brand.

We caution you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. All forward-looking statements speak only as of the date of this presentation. We undertake no obligation to update any forward-looking statements or other information contained herein.

Information regarding market and industry statistics contained in this presentation is included based on information available to us that we believe is accurate. It is generally based on academic and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. Except as required by U.S. federal securities laws, we have no obligation to update forward-looking information to reflect actual results or changes in assumptions or other factors that could affect those statements.



Introduction	Company Overview	4
Our Science	General Scientific Overview	5
Specific Details	Budget Details	6
Final Details	Capital Raise	7
	Our Team	8-12



Overview of company goals and projects

Company history

Biotechnology company dedicated to:

- Researching, developing and commercializing **preventions, treatments and cures** for Alzheimer's
- Working on **two therapeutics** licensed from the **University of South Florida**, one of the top 20 institutions in the nation for patented research and their portfolio of proprietary solutions.

Current projects

AL001 (aka LiProSal): an ionic cocrystal of lithium that may greatly **reduce** or **eliminate** the **symptoms of agitation** and other endpoints for mild to moderate stage patients diagnosed with Alzheimer's.

AL002 (aka CAO22W): adjuvant-free therapeutic vaccine intended for use as a **treatment** or **prophylactic** for patients diagnosed with Alzheimer's.

Product
Development

Commercialization of
Patents

Funding Future
Research

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission.

Overview of our science



Therapeutic Drug	Synopsis	Strength	Status
AL001	<ul style="list-style-type: none"> Use of patented Ionic Cocystal (ICC) technology delivering a therapeutic combination of Lithium, Proline, and Salicylate Lithium as a treatment of agitation and other possible symptoms in patients with indication of Alzheimer's disease Other potential indications: amyotrophic lateral sclerosis (ALS), Huntington disease, multiple sclerosis (MS), Parkinson's disease (PD), traumatic brain injury (TBI), bipolar disorder, depression, mania, post-traumatic stress disorder (PTSD), suicidality, etc. 	<ul style="list-style-type: none"> Exclusive license for Cocystal delivery system to treat Alzheimer's disease Eligible for "breakthrough therapy" designation from FDA Seeking a 505(b)(2) clinical trial pathway from FDA Formulation may importantly expand the range of therapeutic categories amenable to lithium treatments, with enhanced safety Has the potential of becoming the replacement for all lithium therapy on the market 	<ul style="list-style-type: none"> Filed Pre-IND in Q3 2019 Filing IND in Q4 2020 Commencing Phase 1 human clinical trials in Q1 2021
AL002	<ul style="list-style-type: none"> A patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient's immunological system to combat Alzheimer's disease. Also seeks to mitigate adverse reactions from a patient's immunological system experienced during pre-clinical trials including the highly publicized Elan study (AN-1972) Other potential indications: ALS, MS, PD, etc. 	<ul style="list-style-type: none"> Adjuvant-free therapeutic vaccine designed for the treatment and prophylactics of AD Difficult to manufacture and hence not easily replicated by competitors Eligible for "breakthrough therapy" status via FDA Antibody responses induced after one inoculation (Pre-Clinical) and lasted for 4 months Inflammation cytokines like IL1 and TNF.alpha, which are considered being related to inflammation didn't increase with antibody level increase 	<ul style="list-style-type: none"> Completing pre-clinical studies Q4 2020 Filing IND in Q1 2021 Commencing Phase 1 human clinical trials in Q2 2021

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission.

Overview of preliminary budgetary estimate




Category	2020	2021	2022	2023	2024	5-year Total
Phase 1 clinical trial*	\$ -	\$ 7,035,000	\$ -	\$ -	\$ -	\$ 7,035,000
Phase 2 clinical trial*	-	-	20,000,000	7,000,000	-	27,000,000
Phase 3 clinical trial*	-	-	30,000,000	40,000,000	40,000,000	110,000,000
License fees	280,000	400,000	2,425,000	1,000,000	-	4,105,000
Outsourced clinical services	767,000	706,000	475,000	570,000	684,000	3,202,000
SG&A expenses	963,000	3,200,000	2,655,000	2,826,000	3,014,000	12,658,000
Total	\$ 2,010,000	\$ 11,341,000	\$ 55,555,000	\$ 51,396,000	\$ 43,698,000	\$ 164,000,000

*Clinical Trial estimates vary depending on specific requirements from the FDA (Post IND).

*Note: All forecasts are provided by management in this presentation and are based on information available to us at this time and management expects that internal projections and expectations may change over time.
Alzamid Neuro, Inc. information cannot be disclosed or reprinted without prior written permission.*

Overview of capital raise timeline





Stephan Jackman

Chief Executive Officer
20+ years multi-industry experience,
specialized in Biotech and
Pharmaceutical



Kenneth S. Cragun

Chief Financial Officer
30+ Years SEC reporting, Nasdaq CFO,
multi-industry experience, including
Biotech and Healthcare



David Katzoff

SVP Operations
30+ Years multi-industry experience,
including Healthcare and
Technology



Henry Nisser

EVP, General Counsel and
Corporate Secretary
20+ years experience, U.S. securities
compliance, M&A, equity/debt
financings and corporate governance

**Milton "Todd" Ault, III**

Founder/Executive Chairman of Alzamend
Chairman & CEO of DPW Holdings
27+ years Financial Industry experience,
seasoned Wall Street CEO & activist investor

**Stephan Jackman**

Chief Executive Officer
20+ years multi-industry experience, specialized
in Biotech and Pharmaceutical

**William B. Horne**

Chief Financial Officer at DPW Holdings
25+ years Financial Industry experience, prior "Big
4" auditor & healthcare executive

**Henry Nisser**

EVP, General Counsel and Corporate Secretary
20+ years experience, U.S. securities
compliance, M&A, equity/debt financings and
corporate governance

**Philip E. Mansour**

CEO at MTIX International
25+ years multi-industry experience,
seasoned executive, manager & coach

**Eric McDade, DO**

Associate Director, DIAN Trials Unit & Clinical Trials Leadership, Washington University School of Medicine
Associate Professor of Neurology, Washington University School of Medicine
157+ Peer-Reviewed Journal Publications

**Thomas M. Wisniewski, MD**

Director, NYU Langone's Pearl I. Barlow Center for Memory Evaluation and Treatment
300+ Peer-Reviewed Medical Journal Publications (19 U.S. Patents Issued)
Leads a Research Laboratory Continuously Funded by the National Institutes of Health for 20+ Years



Roland Shytle, PhD.

Co-Inventor of AL001 (LiProSal)
Associate Professor, Center of Excellence for Aging & Brain Repair, University of South Florida
30+ Peer-Reviewed Journal Publications (2 U.S. Patents Issued)
30+ Years experience and a leading researcher in Allergy, Immunology and Neurodegenerative Disease



Chuanhai Cao, PhD.

Inventor of AL002 (CAO22W)
Assistant Professor, College of Medicine Neurology, University of South Florida
70+ Peer-Reviewed Journal Publications (4 U.S. Patents Issued)
30+ Years experience and a leading researcher in the field of Alzheimer's treatments



Art Spaulding

Founder and President

25+ years experience, including market research, reimbursement and regulatory



Eve Del Rio, MD, PhD.

Epidemiologist/Immunologist

30+ years experience, including pre-IND, INDs, pre-NDA, NDAs and BLAs



Donald Reitberg, Pharm.D.

Pharmacologist

30+ year experience, including FDA briefing packages for Phases I-IV




Gary W. Wolfe, PhD., DABT

Pharmacologist/Toxicologist

30+ years experience preparing drug development plans for FDA approval

Thank You!

Alzamend 

November 2020